ELTX Share Price Performance
US$10.44
4.28 (69.48%)
89.6% undervalued intrinsic discount
US$100.00
Fair Value
Price US$10.44
Coward_Nutlick US$100.00
Fair ValueUS$100.00
Share Pricen/a
Elicio Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
ELTX Community Narratives
CO
Fair Value US$100 89.6% undervalued intrinsic discount
Very Bullish
5users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
Very Bullish
98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more
718
users have viewed this narrative5users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
CO
US$100
89.6% undervalued intrinsic discount
Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2031
US$140.1
Trending Discussion
Recently Updated Narratives
CO
10 mg adjuvant = 100% mKRAS specific T-cell response rate
Fair Value: US$100 89.6% undervalued intrinsic discount
17 followersusers have followed this narrative
0 commentsusers have commented on this narrative
3 likesusers have liked this narrative
Snowflake Analysis
Elicio Therapeutics, Inc. Key Details
About ELTX
- Founded
- n/a
- Employees
- 33
- CEO
- WebsiteView website
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
